Prime Medicine Inc
PRME3.500USD
-0.070-1.96%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
631.08MMarket Cap
LossP/E TTM
More Details of Prime Medicine Inc Company
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
Prime Medicine Inc Info
Ticker SymbolPRME
Company namePrime Medicine Inc
IPO dateOct 20, 2022
CEOReine (Allan)
Number of employees214
Security typeOrdinary Share
Fiscal year-endOct 20
Address60 First St.
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02141
Phone16174650013
Websitehttps://primemedicine.com/
Ticker SymbolPRME
IPO dateOct 20, 2022
CEOReine (Allan)
Company Executives of Prime Medicine Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Allan Reine, M.D.
Dr. Allan Reine, M.D.
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
125.00K
--
Dr. Ann Louise Lee, Ph.D.
Dr. Ann Louise Lee, Ph.D.
Chief Technical Officer
Chief Technical Officer
100.00K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Chief Business Officer
Chief Business Officer
20.00K
--
Mr. Robert Taylor (Bob) Nelsen
Mr. Robert Taylor (Bob) Nelsen
Independent Director
Independent Director
16.08K
--
Dr. Meredith Goldwasser
Dr. Meredith Goldwasser
Senior Vice President - Strategy and Corporate Operations
Senior Vice President - Strategy and Corporate Operations
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Independent Director
Independent Director
--
--
Ms. Hannah Deresiewicz
Ms. Hannah Deresiewicz
Investor Relations
Investor Relations
--
--
Dr. Andrew Anzalone, M.D., Ph.D.
Dr. Andrew Anzalone, M.D., Ph.D.
Co-Founder, Head of Prime Editing Platform
Co-Founder, Head of Prime Editing Platform
--
--
Dr. Thomas J. Cahill, M.D., Ph.D.
Dr. Thomas J. Cahill, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. David Schenkein, M.D.
Dr. David Schenkein, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Allan Reine, M.D.
Dr. Allan Reine, M.D.
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
125.00K
--
Dr. Ann Louise Lee, Ph.D.
Dr. Ann Louise Lee, Ph.D.
Chief Technical Officer
Chief Technical Officer
100.00K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Chief Business Officer
Chief Business Officer
20.00K
--
Mr. Robert Taylor (Bob) Nelsen
Mr. Robert Taylor (Bob) Nelsen
Independent Director
Independent Director
16.08K
--
Dr. Meredith Goldwasser
Dr. Meredith Goldwasser
Senior Vice President - Strategy and Corporate Operations
Senior Vice President - Strategy and Corporate Operations
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2022
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.11M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Liu (David R)
11.21%
ARCH Venture Partners
10.24%
Alphabet, Inc.
9.18%
T. Rowe Price Investment Management, Inc.
5.11%
Newpath Partners LP
3.38%
Other
60.88%
Shareholders
Shareholders
Proportion
Liu (David R)
11.21%
ARCH Venture Partners
10.24%
Alphabet, Inc.
9.18%
T. Rowe Price Investment Management, Inc.
5.11%
Newpath Partners LP
3.38%
Other
60.88%
Shareholder Types
Shareholders
Proportion
Venture Capital
21.11%
Investment Advisor
20.70%
Individual Investor
14.31%
Hedge Fund
10.74%
Investment Advisor/Hedge Fund
7.21%
Corporation
3.38%
Research Firm
0.87%
Bank and Trust
0.07%
Family Office
0.03%
Other
21.58%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
286
82.91M
47.42%
+2.83M
2025Q2
273
104.91M
62.37%
-18.85M
2025Q1
282
106.20M
80.90%
-20.25M
2024Q4
272
108.78M
82.93%
-18.95M
2024Q3
253
113.13M
92.43%
-10.21M
2024Q2
247
124.37M
103.99%
+15.29M
2024Q1
226
122.24M
102.62%
+28.30M
2023Q4
206
100.04M
102.85%
+26.61M
2023Q3
169
100.64M
103.49%
+30.08M
2023Q2
156
87.82M
90.36%
+22.34M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Liu (David R)
20.24M
11.58%
+84.00K
+0.42%
Jun 30, 2025
ARCH Venture Partners
18.49M
10.57%
+3.03M
+19.61%
Aug 07, 2025
Alphabet, Inc.
15.06M
8.61%
--
--
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
6.48M
3.71%
+2.34M
+56.52%
Jun 30, 2025
Newpath Partners LP
6.11M
3.49%
--
--
Dec 31, 2024
ARK Investment Management LLC
2.32M
1.33%
-772.50K
-24.96%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.07M
2.33%
+144.93K
+3.69%
Jun 30, 2025
The Vanguard Group, Inc.
3.63M
2.07%
-13.84K
-0.38%
Jun 30, 2025
Farallon Capital Management, L.L.C.
750.00K
0.43%
--
--
Jun 30, 2025
Gottesdiener (Keith Michael)
4.36M
2.49%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
2.23%
AXS Green Alpha ETF
1.71%
Invesco Dorsey Wright Healthcare Momentum ETF
0.75%
Global X Genomics & Biotechnology ETF
0.71%
Invesco Dorsey Wright SmallCap Momentum ETF
0.4%
Even Herd Long Short ETF
0.38%
Vanguard US Momentum Factor ETF
0.12%
Invesco Nasdaq Biotechnology ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.08%
iShares Micro-Cap ETF
0.07%
View more
ARK Genomic Revolution ETF
Proportion2.23%
AXS Green Alpha ETF
Proportion1.71%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.75%
Global X Genomics & Biotechnology ETF
Proportion0.71%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.4%
Even Herd Long Short ETF
Proportion0.38%
Vanguard US Momentum Factor ETF
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
iShares Micro-Cap ETF
Proportion0.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Prime Medicine Inc?
The top five shareholders of Prime Medicine Inc are:
Liu (David R) holds 20.24M shares, accounting for 11.58% of the total shares.
ARCH Venture Partners holds 18.49M shares, accounting for 10.57% of the total shares.
Alphabet, Inc. holds 15.06M shares, accounting for 8.61% of the total shares.
T. Rowe Price Investment Management, Inc. holds 6.48M shares, accounting for 3.71% of the total shares.
Newpath Partners LP holds 6.11M shares, accounting for 3.49% of the total shares.
Liu (David R) holds 20.24M shares, accounting for 11.58% of the total shares.
ARCH Venture Partners holds 18.49M shares, accounting for 10.57% of the total shares.
Alphabet, Inc. holds 15.06M shares, accounting for 8.61% of the total shares.
T. Rowe Price Investment Management, Inc. holds 6.48M shares, accounting for 3.71% of the total shares.
Newpath Partners LP holds 6.11M shares, accounting for 3.49% of the total shares.
What are the top three shareholder types of Prime Medicine Inc?
The top three shareholder types of Prime Medicine Inc are:
Liu (David R)
ARCH Venture Partners
Alphabet, Inc.
Liu (David R)
ARCH Venture Partners
Alphabet, Inc.
How many institutions hold shares of Prime Medicine Inc (PRME)?
As of 2025Q3, 286 institutions hold shares of Prime Medicine Inc, with a combined market value of approximately 82.91M, accounting for 47.42% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -14.95%.
What is the biggest source of revenue for Prime Medicine Inc?
In FY2025Q2, the -- business generated the highest revenue for Prime Medicine Inc, amounting to -- and accounting for --% of total revenue.
